SCHEMBL218258

SCHEMBL218258

Cc1ccc(O)c(I)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3947135 0.79 GRM5 (0.46)
SCHEMBL7018653 0.78 S1PR4 (0.52)
SCHEMBL249139 0.76
SCHEMBL5569554 0.76 S1PR4 (0.44)
SCHEMBL23289007 0.74
SCHEMBL21451546 0.74
Methane SCHEMBL6376219 0.74 KDM4E (0.54)
SCHEMBL243044 0.74
SCHEMBL6707376 0.74
SCHEMBL9356023 0.74 KDM4E (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5415685-A Electroplating bath and process for white palladium ENTHONE-OMI INC. (US) 1995-05-16 US claimed
EP-0070198-B1 RADIATION-SENSITIVE COMPOSITION AND PATTERN-FORMATION METHOD USING THE SAME Hitachi, Ltd. (JP) 1985-06-19 EP claimed
EP-0070198-A1 Radiation-sensitive composition and pattern-formation method using the same Hitachi, Ltd. (JP) 1983-01-19 EP claimed
JP-7248624-A None JP disclosed
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 US disclosed
US-20240398776-A1 INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS NEXYS THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
US-12102626-B2 (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer NEXYS THERAPEUTICS, INC. (US) 2024-10-01 US disclosed
US-20240182487-A1 MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2024-06-06 US disclosed
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-03-28 US disclosed
EP-3307676-B1 AQUEOUS COMPOSITION AND METHOD OF PRODUCING CHLORINE DIOXIDE USING AQUEOUS COMPOSITION DIVERSEY INC (US) 2024-02-14 EP disclosed
EP-0604114-A1 Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1994-06-29 EP disclosed
WO-1994005660-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1994-03-17 WO disclosed
WO-1994002464-A1 NEW PYRIDINE DERIVATIVES AS LEUKCOTRIENE B4 ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 1994-02-03 WO disclosed
US-5260294-A Treatment of diseases caused by oxidative metabolism of arachidonic acid; antiinflammatory, antiallergins, antiarthriric HOFFMAN-LA ROCHE INC. (US) 1993-11-09 US disclosed
US-5132310-A Benzochroman compounds, lipoxygenase inhibitors HOFFMANN-LA ROCHE INC. (US) 1992-07-21 US disclosed
US-5015661-A Lipoxygenase inhibitors HOFFMANN-LA ROCHE INC. (US) 1991-05-14 US disclosed
EP-0070198-B1 RADIATION-SENSITIVE COMPOSITION AND PATTERN-FORMATION METHOD USING THE SAME Hitachi, Ltd. (JP) 1985-06-19 EP disclosed
US-4465768-A Pattern-formation method with iodine containing azide and oxygen plasma etching of substrate HITACHI, LTD. (JP) 1984-08-14 US disclosed
EP-0070198-A1 Radiation-sensitive composition and pattern-formation method using the same Hitachi, Ltd. (JP) 1983-01-19 EP disclosed